Stock Analysis
ABIONYX Pharma (EPA:ABNX) First Half 2024 Results
Key Financial Results
- Revenue: €2.34m (up 10.0% from 1H 2023).
- Net loss: €2.09m (loss narrowed by 7.0% from 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ABIONYX Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in France.
Performance of the French Biotechs industry.
The company's shares are down 4.2% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with ABIONYX Pharma (including 1 which makes us a bit uncomfortable).
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ABNX
ABIONYX Pharma
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
